An improved crystal form of Plasmodium falciparum peptide deformylase

Protein Science

Volumn 13, Issue 4, 2004, Pages 1155-1163

  Robien, Mark A ^a   Nguyen, Kiet T ^b   Kumar, Abhinav ^a,c   Hirsh, Irwin ^a,d   Turley, Stewart ^a   Pei, Dehua ^b   Hol, Wim G J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c PLEXXIKON INC   (United States)

^d GE Healthcare Bio Sciences AB   (Sweden)

Author keywords

Crystal engineering; Drug design; Malaria; PDF; Plasmodium

Indexed keywords

ANTIMALARIAL AGENT; ENZYME INHIBITOR; LIGAND; MONOMER; PEPTIDE DEFORMYLASE; TRIPEPTIDE;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; ENZYME ACTIVE SITE; ENZYME ENGINEERING; ENZYME SUBUNIT; EUKARYOTE EVOLUTION; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN DEGRADATION; STRUCTURE ANALYSIS;

AMIDOHYDROLASES; ANIMALS; BINDING SITES; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; PLASMODIUM FALCIPARUM; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

EUKARYOTA; PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 1842611335     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1110/ps.03456404     Document Type: Article

References (23)

1. Apfel, C.M., Evers, S., Hubschwerlen, C., Pirson, W., Page, M.G., and Keck, W. 2001a. Peptide deformylase as an antibacterial drug target: Assays for detection of its inhibition in Escherichia coli cell homogenates and intact cells. Antimicrob. Agents Chemother. 45: 1053-1057.
2. Apfel, C.M., Locher, H., Evers, S., Takacs, B., Hubschwerlen, C., Pirson, W., Page, M. G., and Keck, W. 2001b. Peptide deformylase as an antibacterial drug target: Target validation and resistance development. Antimicrob. Agents Chemother. 45: 1058-1064.
3. Bahl, A., Brunk, B., Crabtree, J., Fraunholz, M.J., Gajria, B., Grant, G.R., Ginsburg, H., Gupta, D., Kissinger, J.C., Labo, P., et al. 2003. PlasmoDB: The Plasmodium genome resource. A database integrating experimental and computational data. Nucleic Acids Res. 31: 212-215.
4. Bracchi-Ricard, V., Nguyen, K.T., Zhou, Y., Rajagopalan, P.T., Chakrabarti, D., and Pei, D. 2001. Characterization of an eukaryotic peptide deformylase from Plasmodium falciparum. Arch. Biochem. Biophys. 396: 162-170.
5. Clements, J.M., Beckett, R.P., Brown, A., Catlin, G., Lobell, M., Palan, S., Thomas, W., Whittaker, M., Wood, S., Salama, S., et al. 2001. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. 45: 563-570.
6. Cowtan, K. and Main, P. 1998. Miscellaneous algorithms for density modification. Acta Crystallogr. D Biol. Crystallogr. 54: 487-493.
7. Gewirth, D., Otwinowski, Z., and Majewski, W. 1996. The HKL2000 manual, 5th ed. Yale University, New Haven, CT.
8. Hackbarth, C.J., Chen, D.Z., Lewis, J.G., Clark, K., Mangold, J.B., Cramer, J.A., Margolis, P.S., Wang, W., Koehn, J., Wu, C., et al. 2002. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother. 46: 2752-2764.
9. Kraulis, P.J. 1991. Molscript - A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24: 946-950.
10. Kumar, A., Nguyen, K.T., Srivathsan, S., Ornstein, B., Turley, S., Hirsh, I., Pei, D., and Hol, W.G. 2002. Crystals of peptide deformylase from Plasmodium falciparum reveal critical characteristics of the active site for drug design. Structure 10: 357-367.
11. Merritt, E.A. and Bacon, D.J. 1997. Raster3D: Photorealistic molecular graphics. Macromol. Crystal. Pt B 277: 505-524.
12. MOE (The Molecular Operating Environment) Version 2003.02. Software. Chemical Computing Group Inc., Montreal, Canada. http://www.chemcomp. com.
13. Murshudov, G.N., Vagin, A.A., and Dodson, E.J. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53: 240-255.
14. Nguyen, K.T., Hu, X., Colton, C., Chakrabarti, R., Zhu, M.X., and Pei, D. 2003. Characterization of a human peptide deformylase: Implications for antibacterial drug design. Biochemistry 42: 9952-9958.
15. Read, R.J. 1986. Improved Fourier coefficients for maps using phases from partial structures with errors. Acta Crystallogr. A 42: 140-149.
16. Roblin, P.M. and Hammerschlag, M.R. 2003. In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 47: 1447-1448.
17. Vagin, A. and Teplyakov, A. 1997. MOLREP: An automated program for molecular replacement. J. Appl. Cryst. 30: 1022-1025.
18. van Aalten, D.M., Bywater, R., Findlay, J.B., Hendlich, M., Hooft, R.W., and Vriend, G. 1996. PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules. J. Comput. Aided Mol. Des. 10: 255-263.
19. Weiss, M.S. 2001. Global indicators of X-ray data quality. J. Appl. Crystallogr. 34: 130-135.
20. WHO Expert Committee on Malaria. 2000. World Health Organ Tech. Rep. Ser. 892.
21. Wiesner, J., Sanderbrand, S., Altincicek, B., Beck, E., and Jomaa, H. 2001. Seeking new targets for antiparasitic agents. Trends Parasitol. 17: 7-8.
22. Wise, R., Andrews, J.M., and Ashby, J. 2002. In vitro activities of peptide deformylase inhibitors against gram-positive pathogens. Antimicrob. Agents Chemother. 46: 1117-1118.
23. Yeh, J.I. and Hol, W.G. 1998. A flash-annealing technique to improve diffraction limits and lower mosaicity in crystals of glycerol kinase. Acta Crystallogr. D Biol. Crystallogr. 54: 479-480.